Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.
Mitsushige Sugimoto,Hiromitsu Ban,Daiki Hira,Takaki Kamiya,Taketo Otsuka,Osamu Inatomi,Shigeki Bamba,Tomohiro Terada,Akira Andoh +8 more
Reads0
Chats0
TLDR
A simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection and the epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan is proposed.Abstract:
1. Takyar V, Surana P, Kleiner DE, et al. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther 2017; 45: 127–38. 2. Kayadibi H. Letter: changes in FIB-4 cut-off points for viral hepatitis. Aliment Pharmacol Ther 2017; 45: 1007–8. 3. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749–56. 4. Toukan AU, Abu-el-Rub OA, Abu-Laban SA, et al. The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan. Hepatology 1987; 7: 1340–5. 5. Verme G, Brunetto MR, Oliveri F, et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991; 36: 1134–6. 6. Liao BL, Zhang FC, Lin SW, et al. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS ONE 2014; 9: e115888. 7. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–25.read more
Citations
More filters
Journal ArticleDOI
Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
TL;DR: The potassium-competitive acid blocker vonoprazan (VPZ) became clinically available in Japan in 2015 and a VPZ-containing H. pylori eradication regimen is expected to increase the eradication rate compared with conventional regimens containing a standard dose of PPI.
Journal ArticleDOI
Efficacy of Vonoprazan for Helicobacter pylori Eradication.
TL;DR: The current situation of H. pylori eradication in Japan is reviewed and vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs).
Journal ArticleDOI
Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
TL;DR: A comprehensive literature search including Medline (PubMed), EMBASE, Web of Science and the Cochrane Library from inception until November 2020, for studies of the clinical pharmacology of P-CABs and relevant clinical trials of those that are currently licensed or in development was conducted in this article.
Journal ArticleDOI
Helicobacter pylori therapy and clinical perspective.
TL;DR: The performance of antimicrobial susceptibility testing before any antimicrobial prescription is recommended, and a potential increase in efficacy of future therapies may be influenced by adding the novel potassium-competitive acid blocker vonoprazan.
Journal ArticleDOI
Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy
TL;DR: Genotyping for CYP 3A4, CYP3A5 and CYP2C19 before vonoprazan-containing eradication treatment may not be useful for predicting clinical outcomes.
References
More filters
Journal ArticleDOI
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
TL;DR: Despite a strong association between the CYP3A5 6986A>G SNP and tacrolimus pharmacokinetics, there is no consistent evidence of organ rejection as a result of genotype-related under-immunosuppression, with studies showing conflicting results in regard to the main parameters of acute rejection and nephrotoxicity.
Journal ArticleDOI
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
TL;DR: Vonoprazan is effective as part of first-line triple therapy and aspart of second- line triple therapy in H pylori-positive patients with a history of gastric or duodenal ulcer.
Journal ArticleDOI
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
TL;DR: Vonoprazan is a member of a new class of acid suppressants; potassium‐competitive acid blockers; and may be an alternative to PPIs.
Journal ArticleDOI
Effect of Omeprazole on the Distribution of Metronidazole, Amoxicillin, and Clarithromycin in Human Gastric Juice
A. F. Goddard,M.J. Jessa,David A. Barrett,Paul N. Shaw,J-P. Idström,C Cederberg,Robin C. Spiller +6 more
TL;DR: Novel pharmacokinetic parameters have been described that provide an insight into the mechanisms underlying drug transfer across the blood-stomach barrier and increases intragastric concentrations of amoxicillin partly by reducing gastric juice volume.
Journal ArticleDOI
Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.
M L Grayson,George M. Eliopoulos,George M. Eliopoulos,M. J. Ferraro,Robert C. Moellering,Robert C. Moellering +5 more
TL;DR: The effect of pH an antimicrobial efficacy may warrant consideration when selecting an antibiotic to clearCampylobacter pylori in vivo, since the pH of the gastric submucous environment is not known for certain.